biologic

Cosentyx

secukinumab

Loss of exclusivityMay 2033projected — 12-year biologic exclusivity estimate
CompanyNovartis Pharmaceuticals Corporation

Drug detail

Brand nameCosentyx
Active ingredientsecukinumab
Strength75MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.